ARDS亚表型的潜在类别分析:脓毒症急性肺损伤他汀治疗(SAILS)研究的二次分析
本研究为SAILS试验的二次分析,使用基线生物标志物和临床数据进行潜在类别分析,纳入745例感染相关ARDS患者。两类别模型拟合最佳,40%患者被分类为高炎症亚表型,该亚表型60天和90天死亡率更高。加入更多临床变量未发现新类别。高炎症亚表型患者随机接受瑞舒伐他汀与安慰剂相比,结局无差异。研究验证了ARDS两个亚表型的存在及其用于患者分层的价值。
要点
- 在SAILS研究745例感染相关ARDS患者中,两类别潜在类别模型拟合最佳,40%被分类为高炎症亚表型。
- 高炎症亚表型患者60天和90天死亡率高于另一亚表型。
- 高炎症亚表型患者随机接受瑞舒伐他汀治疗与安慰剂相比,结局无差异。
- 在潜在类别模型中加入额外临床变量未识别出新的类别。
- 两类别亚表型特征与既往四个队列报道一致,支持其用于ARDS患者分层。
适用人群与场景
- 感染相关ARDS患者,来自SAILS研究,样本量n=745。
研究设计与关键结果
- 研究类型:SAILS试验的二次分析,使用潜在类别分析。
- 样本量:n=745。
- 两类别潜在类别模型最佳拟合SAILS人群,40%患者为高炎症亚表型。
- 高炎症亚表型患者60天和90天死亡率更高。
- 高炎症亚表型患者随机接受瑞舒伐他汀治疗与安慰剂相比,结局无差异。
- 在潜在类别模型中加入额外临床变量未识别出新类别。
证据类型、等级与局限
- 证据类型:随机对照试验的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 潜在类别分析可在ARDS患者中识别两个亚表型,高炎症亚表型与更差预后相关,可能有助于患者分层。
- 在本研究中,高炎症亚表型患者接受瑞舒伐他汀治疗与安慰剂相比未见结局差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Using latent class analysis (LCA), we have consistently identified two distinct subphenotypes in four randomized controlled trial cohorts of ARDS. One subphenotype has hyper-inflammatory characteristics and is associated with worse clinical outcomes. Further, within three negative clinical trials, we observed differential treatment response by subphenotype to randomly assigned interventions. The main purpose of this study was to identify ARDS subphenotypes in a contemporary NHLBI Network trial of infection-associated ARDS (SAILS) using LCA and to test for differential treatment response to rosuvastatin therapy in the subphenotypes.
METHODS: LCA models were constructed using a combination of biomarker and clinical data at baseline in the SAILS study (n = 745). LCA modeling was then repeated using an expanded set of clinical class-defining variables. Subphenotypes were tested for differential treatment response to rosuvastatin.
RESULTS: The two-class LCA model best fit the population. Forty percent of the patients were classified as the "hyper-inflammatory" subphenotype. Including additional clinical variables in the LCA models did not identify new classes. Mortality at day 60 and day 90 was higher in the hyper-inflammatory subphenotype. No differences in outcome were observed between hyper-inflammatory patients randomized to rosuvastatin therapy versus placebo.
CONCLUSIONS: LCA using a two-subphenotype model best described the SAILS population. The subphenotypes have features consistent with those previously reported in four other cohorts. Addition of new class-defining variables in the LCA model did not yield additional subphenotypes. No treatment effect was observed with rosuvastatin. These findings further validate the presence of two subphenotypes and demonstrate their utility for patient stratification in ARDS.
参考来源
- Sinha P, Delucchi KL, Thompson BT, et al. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med. 2018. PMID: 30291376. doi:10.1007/s00134-018-5378-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。